Achaogen Stock

AKAOQ

US0044491043

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

20-06-11	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
20-05-29	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 559K 515K 474K 897K 61.47M 913K 6.15M 2.41M 30.04M 2.4M 2.35M 104M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 17.02M 15.7M 14.43M 27.35M 1.87B 27.81M 187M 73.55M 916M 73.11M 71.5M 3.16B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

20-06-11	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
20-05-29	Achaogen, Inc. Went Out of Business	CI
20-05-29	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
20-04-22	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
20-04-21	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
20-03-30	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
20-01-08	Motion for Asset Sale Approved for Achaogen, Inc.	CI
19-12-29	Motion for Asset Sale Filed by Achaogen, Inc.	CI
19-09-24	Final DIP Financing Approved for Achaogen, Inc.	CI
19-08-29	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
19-08-13	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
19-07-29	Achaogen, Inc. Announces Management Changes	CI
19-07-23	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 9.77M 9.01M 8.29M 15.7M 1.08B 15.97M 108M 42.22M 526M 41.97M 41.05M 1.81B	8.73M 7.63M 7.04M 6.47M 12.26M 840M 12.47M 84.04M 32.97M 410M 32.78M 32.06M 1.41B
Net income	-126M -110M -101M -93.13M -176M -12.09B -179M -1.21B -475M -5.91B -472M -461M -20.36B	-187M -163M -150M -138M -262M -17.95B -266M -1.8B -705M -8.77B -700M -685M -30.23B
Net Debt	-143M -125M -115M -106M -201M -13.74B -204M -1.38B -540M -6.72B -536M -525M -23.15B	18.83M 16.46M 15.19M 13.96M 26.45M 1.81B 26.9M 181M 71.13M 885M 70.71M 69.16M 3.05B

Achaogen Stock

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news : Achaogen

Financials

Company Profile